ライフサイエンスコーパス: salvage chemotherapy

1 to conventional therapeutic approaches (eg, salvage chemotherapy).

2 sease free at more than 5 and 22 years after salvage chemotherapy.

3 ssical Hodgkin lymphoma (cHL) who respond to salvage chemotherapy.

4 patients may benefit more from conventional salvage chemotherapy.

5 inhibitor, improves overall survival versus salvage chemotherapy.

6 patients may benefit more from conventional salvage chemotherapy.

7 al chemotherapy are potentially curable with salvage chemotherapy.

8 reated resection cavity (SCRC) and then with salvage chemotherapy.

9 poor predicted outcome to conventional-dose salvage chemotherapy.

10 able prognostic factors to conventional-dose salvage chemotherapy.

11 ell rescue (ASCT) compared with conventional salvage chemotherapy.

12 independent prognostic factors for PFS after salvage chemotherapy.

13 al BEP chemotherapy are usually treated with salvage chemotherapy.

14 e seminoma have resistant tumors and require salvage chemotherapy.

15 ve durable CR with conventional or high-dose salvage chemotherapy.

16 e, advanced, pure seminoma were treated with salvage chemotherapy.

17 ymphoma (NHL) after failures of standard and salvage chemotherapy.

18 f 24 (54%) are long-term survivors with VeIP salvage chemotherapy.

19 improves survival compared with conventional salvage chemotherapy.

20 d irradiation and five patients who received salvage chemotherapy.

21 germ cell tumours (GCTs) might be cured with salvage chemotherapy.

22 isease after completing either first-line or salvage chemotherapy.

23 , 24 patients were treated with conventional salvage chemotherapy, 14 patients were treated with high

24 nts experiencing relapse received successful salvage chemotherapy (4-year OS, 96%; 95% CI, 74% to 99%

25 In patients with RRHL receiving salvage chemotherapy (92.4%), common regimens were ESHAP

26 High-dose chemotherapy as initial salvage chemotherapy achieved impressive long-term survi

27 without PD-1 blockade, and the rest received salvage chemotherapy alone.

28 Standard salvage chemotherapy and donor lymphocyte infusions (DLI

29 th quizartinib had a survival benefit versus salvage chemotherapy and had a manageable safety profile

30 ith relapsed or refractory lymphoma received salvage chemotherapy and were randomized to have HPC mob

31 one marrow transplantation rescue as initial salvage chemotherapy at Indiana University.

32 the ASAP trial was conducted to test RIST by salvage chemotherapy before alloHCT against immediate tr

33 al showed no survival advantage for standard salvage chemotherapy before alloHCT as opposed to immedi

34 y best clinical response after completion of salvage chemotherapy (complete response vs partial respo

35 in lymphoma could be treated with multiagent salvage chemotherapy followed by autologous haematopoiet

36 hat for non-HIV-cHL, and includes the use of salvage chemotherapy followed by autologous stem cell tr

37 large B-cell lymphoma (DLBCL) compared with salvage chemotherapy followed by hematopoietic stem cell

38 eucel (axi-cel)) over standard of care (SOC; salvage chemotherapy followed by hematopoietic transplan

39 sed diffuse large B-cell lymphoma (DLBCL) is salvage chemotherapy followed by high-dose therapy and a

40 loleucel and tisagenlecleucel) compared with salvage chemotherapy followed by HSCT.

41 itional cycles of standard-dose etoposide as salvage chemotherapy for germ cell tumors.

42 Salvage chemotherapy for recurrent chest wall lesions in

43 15 after primary chemotherapy and nine after salvage chemotherapy for relapsed HL.

44 5 micro g/kg (n = 33) in patients receiving salvage chemotherapy for relapsed or refractory Hodgkin'

45 otherapy (group A) and for 10 patients after salvage chemotherapy (group B).

46 Relapse after salvage chemotherapy has a poor prognosis and the optima

47 side was first used at Indiana University as salvage chemotherapy in 1978, representing the first tim

48 ne therapy in early-stage breast cancer, and salvage chemotherapy in advanced ovarian cancer.

49 be the response to conventional or high-dose salvage chemotherapy in patients with advanced seminoma

50 yte colony-stimulating factor (G-CSF) (FLAG) salvage chemotherapy in patients with refractory or rela

51 nvestigate optimal CSI doses and the role of salvage chemotherapy in this population.

52 on in a patient with head and neck cancer on salvage chemotherapy, including the epidermal growth fac

53 131)I-apamistamab group and 28-42 days after salvage chemotherapy initiation; patients without CR/CRp

54 The benefit of salvage chemotherapy is modest in metastatic urothelial

55 ) who achieve a partial remission (PR) after salvage chemotherapy is not known.

56 Twenty-nine patients received salvage chemotherapy on a clinical trial for late relaps

57 the approaches to clinical stage I disease, salvage chemotherapy, post-chemotherapy surgical procedu

58 It incorporates primary, adjuvant, and salvage chemotherapy, primary and post-chemotherapy RPLN

59 Cetuximab, used alone or with salvage chemotherapy, produces clinically meaningful ant

60 Because patients who undergo conventional salvage chemotherapy programs rarely achieve long-term d

61 age I EOC can be successfully treated with a salvage chemotherapy regimen after a policy of observati

62 latin-containing regimen were treated with a salvage chemotherapy regimen of ifosfamide, cisplatin, a

63 mor (FHWT) and recurrence after at least one salvage chemotherapy regimen or with anaplastic histolog

64 -C) is an essential component of primary and salvage chemotherapy regimens for acute myeloid leukemia

65 Salvage chemotherapy regimens integrating dose dense and

66 he leukemia burden prior to transplantation, salvage chemotherapy regimens need to be employed.

67 Eight of 34 patients (24%) who received salvage chemotherapy responded.

68 rmed indolent lymphoma (TRIL) often includes salvage chemotherapy (SC) and autologous stem cell trans

69 Eight patients underwent resection after salvage chemotherapy; six with histologic findings of ne

70 r, extranodal disease, and B symptoms before salvage chemotherapy (SLT) can stratify relapsed or refr

71 ose (FDG-PET) has not been established after salvage chemotherapy (ST) and before HDT-ASCT by modern

72 atients with refractory or relapsed disease, salvage chemotherapy still offers little chance of long-

73 sitive on positron emission tomography after salvage chemotherapy, the 16-month PFS was 0.70 (90% CI,

74 After three cycles of salvage chemotherapy, the responding patients received h

75 cally remain hospitalized after induction or salvage chemotherapy until blood cell count recovery, wi

76 nts (73%) received salvage CSI, and although salvage chemotherapy was not significant in multivariabl

77 cycles of bleomycin, etoposide, and platinum salvage chemotherapy was performed for five patients who

78 46 patients treated on a clinical trial with salvage chemotherapy was performed; 29 patients with lat

79 CR rates following salvage chemotherapy were 32% to 33% in the simultaneous

80 complete or very good partial remission with salvage chemotherapy were randomly assigned using a fact

81 or progressive disease at any time received salvage chemotherapy with cisplatin and etoposide.

82 e long-term survival and potential cure with salvage chemotherapy with paclitaxel plus gemcitabine af

83 cer patients will subsequently be cured with salvage chemotherapy with tandem transplant of high-dose